The present invention concerns a composition, preferably a cosmetic composition, comprising, in a physiologically acceptable medium, at least mulberroside A and rnulberroside E. It also relates to the use of such a composition for depigmenting, lightening and/or bleaching keratin materials, in particular the skin.
The human skin color is primarily determined by the nature and concentration of a pigment, melanin. There are two types of melanin in skin cells: eumelanin, a brown-black pigment, and pheomelanin, a yellow-red pigment. Melanin is synthesized by specific
dendritic cells, called melanocytes, located in the basal layer of the epidermis.
Melanogenesis, i.e. the formation of melanin, takes place in special organelles, the meianosomes, which, loaded with melanin, are transferred to the neighboring epidermal cells (keratinocytes) via dendrites. The mechanism of melanogenesis is particularly complex and schematically involves the following main steps inside the meianosomes: Tyrosine ~> Dopa -> Dopaquinone -> Dopacbrome -> Melanin.
Tyrosinase (monophenol dihydroxy! phenylalanine: oxygen oxido reductase EC1.14.18.1} is the essential enzyme involved in this sequence of reactions. It catalyzes the reaction for conversion of tyrosine into dopa (dihydroxyphenylaianine) by means of its hydroxylase activity, and the reaction for conversion of dopa into dopaquinone by means of its oxidase activity. This tyrosinase acts only when it is in mature form under the action of certain biological factors.
The pigmentation of the facial skin and/or body, especially the skin pigmentation, is based on factors such as environmental factors related to seasons and the origin of the individual.
In addition, at different periods of their lives, some people see the appearance on their skin, and more in particular on the hands, of darker and/or more colored spots, which give the skin heterogeneity. These spots are in particular due to a high concentration of melanin in the keratinocytes located at the surface of the skin.
Thus, when the pigmentation process is altered, it can result in pigmentation defects, hypopigmentation, or conversely in an excess of pigmentation, hype rpig mentation. Among the benign pigmentary changes characterized by abnormal

accumulation (not tanning) of melanin, one can mention actinic lentigo (also called solar lentigo or more commonly "sunspots"), senile lentigo (commonly known as "age spots" or "senile scum", "cemetery daisies" or "graveyard flowers"), lentigines and freckles.
Many processes, preferably cosmetic processes, have therefore been developed to try to eliminate or reduce the presence of these benign pigmentary changes. Eliminating or reducing the presence of these alterations is usually based on the application of depigmenting treatments, which reduce melanin synthesis activity in melanocytes. The depigmenting molecules are distinct from anti-pigrnenting molecules that limit the action of the stress responsible for pigmentation due to ultraviolet radiation.
More specifically, a molecule is recognized as depigmenting if, in particular, it interferes with one of the steps in the biosynthesis of melanin, either by inhibiting one of the enzymes involved in melanogenesis, or by being inserted as a structural analogue of one of the chemical compounds of the melanin synthesis, which may then be blocked and thus ensure depigmentation.
One of the main avenues explored to date is based on the inhibition of tyrosinase. The purpose of these treatments is to reduce or even stop the synthesis of the pigment.
Classical known depigmenting substances are hydroquinone and its derivatives, particularly its ethers such as monomethyl ether and hydroquinone monoethyl ether, kojic acid, arbutin, the irninophenols or ascorbic acid and its derivatives.
However, there are major drawbacks associated with the use of the above depigmenting agents. Indeed, depigmenting substances may especially be unstable, and/or show low efficiency at low concentration or toxic or allergenic properties.
In this regard, the Applicant has discovered, surprisingly and unexpectedly, that specific mixtures of compounds present in white mulberries have good depigmenting activity, even at low concentration.
The present Invention thus relates to a composition comprising, in a physiologically acceptable medium, at least muiberroside A and mulberroside E ("composition of the invention" or "composition according to the invention"). Preferably, such a composition is a cosmetic composition.

The composition according to the invention can efficiently depigment and/or lighten, or even bleach, human skin. It is in particular intended to be applied to the skin of individuals bearing brownish pigmentation spots or senescence spots, or to the skin of individuals wishing to combat the appearance of a brownish color caused by melanogenesis. \t may also make it possible to depigment and/or lighten bodily hairs, the eyelashes, head hair and/or also the lips.
The composition according to the invention, comprising a mixture of at feast mulberrosides A and E, indeed shows a beneficial enhanced depigmenting efficacy compared to mulberroside A alone.
The present invention also relates to the cosmetic use of a composition of the invention, for depigmenting, lightening and/or bleaching keratin materials, in particular the skin.
The present invention further relates to a cosmetic non-therapeutic process for depigmenting, lightening and/or bleaching keratin materials, in particular the skin, comprising a step of applying a composition of the invention onto the keratin materials, in particular the skin.
The term "keratin materials" means skin, hair, eyelashes, and nails.
The term "skin" refers to the entire body skin, including the scafp, mucous membranes and semi-mucous membranes, and its annexes. Specifically, it is considered in the present invention the skin of the chest, neck and face, hands, armpits and especially facial skin.
CcjTTgo^jtswi^UteJny^nJic^
The composition of the invention, preferably cosmetic composition, comprises, in a physiologically acceptable medium, at least mulberroside A and mulberroside E.
Preferably, the composition of the invention comprises, in a physiologically acceptable medium, an extract which comprises at least mulberroside A and mulberroside E. The extract which comprises at least mulberroside A and mulberroside E may be a vegetal extract, or a synthetic extract.
By vegetal extract, it is meant an extract from plants and/or trees.

4
By synthetic extract, it is meant a formulation made up of (i) at least mulberroside A and mulberroside E, and (ii) a vehicle, which may be aqueous or non-aqueous, and which is compatible with an application onto keratin materials.
5 Preferably, the extract which comprises at least mulberroside A and mulberroside E
is a vegetal extract. Preferably, the vegetal extract is an extract from white mulberries
(also called Morus alba), particularly white mulberry twigs.
Thus, preferably, the composition of the invention comprises a Morus alba exXract.
10 More preferably, the composition of the invention comprises a Morus alba twig extract.
White mulberry, also called Morus alba, grows as a dense, round-topped, perennial shrub or tree, reaching heights around 50 feet (15 m). The thin bark is shallowly furrowed and has long, narrow ridges. White mulberry leaves are alternate, simple, ovate, 2 to 4
15 inches (6-10 cm) long and 1 to 2 inches (3-6 cm) wide, with margins varying from coarsely
serrate to deeply iobed and serrate. Leaves Qmtie a milky juice when broken. Staminate and pistillate flowers develop in separate catkins. Plants are typically dioecious and occasionally monoecious. White mulberry fruits are cylindrical drupes, 0.5 to 1.0 inches (1.5-2.5 cm) long. Fruits may be black, purple, or white. The ovoid nutlet has a thin, soft
20 shell, and the seed has a "hard bony coat".
China is the largest producer of white mulberry and silk in the world. Preferably, the white mulberry comes from China, especially from Chongqing city.
Mulberroside A belongs to stilbenoids; it is the diglucoside of oxyresveratrol. Its
25 chemical name is (2S,3R,4S,5S,6R)-2-[3-hvdroxy-4-[(E)-2-[3-hydroxy-5-
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxyphenyl]ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol, and it is the "E" diastereoisomer. It has the following formula (i):

(I) OH OH

Mulberroside E also belongs to stilbenoids. Its chemical name is 4-[(1 E)-2-[3-(j3-D-Glucopyranosyloxy)-5-hydroxyphenyl]ethenyl]phenyl-£-D-glucopyranoside. It has the following formula (II):

(II)

HON

r T 'i r°i' ^OH
°\^°\r^\/^^ "^^HOy V1 ^OH
Y '''OH y^ OH
OH OH

10

Preferably, the extract comprises at least 15% by weight of the total weight of the extract, of mulberroside A, preferably at least 17% by weight. Preferably, the extract comprises less than 50% by weight of the total weight of the extract, of mulberroside A, preferably less than 45% by weight, preferably less than 40% by weight. Preferably, the extract comprises from 15% to 40% by weight of the total weight of the extract, of mulberroside A.

Preferably, the extract comprises at least 3% by weight of the total weight of the
extract, of mulberroside E, preferably at least 4% by weight. Preferably, the extract
15 comprises less than 15% by weight of the total weight of the extract, of mulberroside E,
preferably less than 10% by weight, preferably less than 8% by weight. Preferably, the extract comprises from 4% to 8% by weight of the total weight of the extract, of mulberroside E.
20 Preferably, the composition of the invention further comprises cis-mulberroside A.
Cis-mulberroside A is the "Z" diastereoisomer of mulberroside A ("cis"). Its chemical name is 3"[(1Z)-2-t4-(|3-D"Glucopyranosyloxy)-2-hydroxyphenyl]etheny!]-5-hydroxyphenyl-p-D-glucopyranoside. It has the following formula (111):


H OH
HO,,, J^.^OH
OH
O" O

25

cr o

6
Preferably, the extract further comprises cis-mulberroside A.
Preferably, the extract comprises at least 0,2% by weight of the total weight of the
extract, of cis-mulberroside A, preferably at least 0,4% by weight, preferably at least 0,5%
by weight. Preferably, the extract comprises less than 5% by weight of the total weight of
5 the extract, of cis-mulberroside A, preferably less than 4% by weight, preferably less than
2% by weight. Preferably, the extract comprises from 0,5% to 2% by weight of cis-mulberroside A.
Preferably, the composition of the invention further comprises at least one
10 compound chosen from mulberroside F, cis-oxyresveratroi-3'-0~p-glucopyranoside, trans-
oxyresveratrol-3-0-$-glucopyranoside, oxyresveratroi, and their mixtures.
Preferably, the extract further comprises at least one compound chosen from
mulberroside F, cis-oxyresveratrol~3'-Op-glucopyranoside, trans-oxyresveratrol-3-O-p-
15 glucopyranoside, oxyresveratroi, and their mixtures.
Preferably, the composition of the invention or the extract further comprises
mulberroside F. Its chemical name is 3~[6-(p-D-Glucopyranosyloxy)-2-benzofuranyl]-5-hydroxypheny! p-D-glucopyranoside. It corresponds to the following formula (IV):

OH HO^l0J,0
20 (IV)
Preferably, the extract comprises at least 0,4% by weight of the total weight of the
extract, of mulberroside F, preferably at least 0,5% by weight. Preferably, the extract
comprises less than 5% by weight of the total weight of the extract, of mulberroside F,
25 preferably less than 3% by weight, preferably less than 2% by weight. Preferably, the
extract comprises from 0,5% to 2% by weight of the total weight of the extract, of mulberroside F.
Preferably, the composition of the invention or the extract further comprises cis-
30 oxyresveratroi-3'-Q-p-glucopyranoside. Its chemical name is 3-[(1 Z)-2-(2,4-
It corresponds to the following formula (V):

(V)

10
15

PreferabSy, the extract comprises at least 0,4% by weight of the total weight of the extract, of cis-oxyresveratroi-S'-O-p-glucopyranoside, preferably at least 0,5% by weight. Preferably, the extract comprises less than 5% by weight of the total weight of the extract, of cis-oxyresveratrol-3'-0-p-glucopyranoside, preferably less than 3% by weight, preferably less than 2% by weight. Preferably, the extract comprises from 0,5% to 2% by weight of the total weight of the extract, of cis-oxyresveratrol-3'-0|3-g!ucopyranoside.
Preferably, the composition of the invention or the extract further comprises trans-oxyresveratroi-S'-O-p-glucopyranoside. its chemical name is 3-[(1E)-2-(2,4-Dihydroxyphenyi)ethenyl]-5-hydroxyphenyl $-D-glucopyranoside. it corresponds to the
following formula (VI):
HCL ^^ X>H


(VI)
Preferably, the extract comprises at least 0,4% by weight of the total weight of the extract, of trans-oxyresveratrol-3'-0-p-glucopyranoside, preferably at least 0,5% by 20 weight. Preferably, the extract comprises less than 5% by weight of the total weight of the extract, of trans-oxyresveratrol-3'-0-p-glucopyranoside, preferably less than 3% by weight, preferably less than 2% by weight. Preferably, the extract comprises from 0,5% to 2% by weight of the total weight of the extract, of trans-oxyresveratrol-3'-0-(V glucopyranoside.
25
Preferably, the composition of the invention or the extract further comprises oxyresveratrol. Oxyresveratrol has the chemical name 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol, and corresponds to the following formula (VII):


Preferably, the extract comprises at least 0,1% by weight of the total weight of the
extract, of oxyresveratrol, preferabSy at least 0,2% by weight. Preferably, the extract
5 comprises less than 3% by weight of the total weight of the extract, of oxyresveratrol,
preferably less than 2% by weight, preferably less than 1% by weight. Preferably, the extract comprises from 0,3% to 1% by weight of the total weight of the extract, of oxyresveratrol.
10 More preferably, the extract comprises:
- at least 0,4%, preferably 0,5% to 2% by weight of mulberroside F, and/or
- at least 0,4%, preferably 0,5% to 2% by weight of cis-oxyresveratrol-3'-0-p-glucopyranoside, and/or

- at least 0,4%, preferably 0,5% to 2% by weight of trans-Gxyresveratrol-3-O-p-15 glucopyranoside, and/or
- at least 0,2%, preferably 0,3% to 1 % by weight of oxyresveratrol.
Preferably, the composition of the invention comprises from 0,1% to 0,5% by weight
preferably from 0,2% to 0,5% by weight of the total weight of the composition, of the
20 extract.
Prepaxalioj3_Qfthe_exlract
The composition of the invention preferably comprises a vegetal extract which
comprises at least mulberroside A and mulberroside E.
25 More preferably, the composition of the invention comprises a Morus alba extract,
more preferably a Morus alba twig extract.
Such a Morus alba twig extract may be prepared as described in example 1.
30 Phyj$ic4oj3iCi^^
medium. The term "physiologically acceptable [medium" is intended to mean a medium

9 that is compatible with human keratin materials, such as the skin of the body or of the face, the lips, the mucous membranes, the eyelashes, the nails, the scalp and/or the hair.
The composition used according to the invention may then comprise any adjuvant
commonly used in the cosmetics field. Mention may be made in particular of an aqueous
5 phase, which comprises water and optionally organic solvents; and/or an oily phase,
which comprises at least one oil and/or wax. Mention may also be made of pigments,
fillers, dyes, surfactants, emulsifiers; cosmetic or dermatologica! active agents, UV-
screening agents (mineral or organic, anti-UVA and/or anti-UVB), polymers, hydrophilic or
lipophilic gelling agents, thickeners, preservatives, fragrances, bactericides, ceramides,
10 odor absorbers and antioxidants.
The composition according to the invention preferably comprises an aqueous
medium comprising water and possibly an organic solvent soluble in water at 25°C,
chosen for example from among linear or branched alkanols, in C2-C4, such as ethanol
15 and isopropanol, propanol, butanol; polyols particularly with 2 to 20 carbon atoms,
preferably 2 to 6 carbon atoms such as glycerol, diglycerol, propyleneglycol, glycol isoprene, dipropyleneglycol, butylene glycol, hexylene glycol, 1,3-propanediol, pentylene glycol, polyethyleneglycols with 2 to 200 ethylene oxide motifs, and mixtures thereof.
The composition generally comprises from 10% to 99% by weight of water with
20 respect to the total weight of the composition and preferably from 30% to 80%.
The quantity of organic solvents can range for example from 0% to 30% by weight, preferably from 0.5% to 25% by weight, better from 5% to 20% by weight, even better from 10% to 20% by weight relative to the total weight of the composition.
25 The composition according to the invention may also comprise an oily phase.
When the composition used according to the invention comprises an oily phase, this oily phase preferably contains at least one oil, particularly a cosmetic oil. It may further contain other fats.
By way of oils suitable for use in the composition according to the invention,
30 mention may be made for example of hydrocarbon oils of animal origin; hydrocarbon oils
of plant origin; esters and synthetic esters, in particular fatty acids, such as oils having formulas R1COOR2 and R10R2 wherein R1 is the remainder of a fatty acid comprising from 8 to 29 carbon atoms, and R2 is a hydrocarbon chain, branched or not, containing from 3 to 30 carbon atoms; hydroxylated esters; polyol esters; linear or branched
35 hydrocarbons, with inorganic or synthetic origin, hydrocarbon oils with branched chain
containing 10 to 20 carbon atoms, vaseline, polydecenes, hydrogenated polyisobutene;

10 natural or synthetic essential oils; fatty alcohols having 8 to 26 carbon atoms; partially hydrocarbon and/or silicone fluorinated oils such as those described in the document JP-A-2-295912; silicone oils such as polymethylsiloxanes (PDMS), optionally volatile; or mixtures thereof. 5
The other fats suitable for being present in the oil phase are for example fatty acids comprising 8 to 30 carbon atoms; waxes; silicone resins; and silicon elastomers and mixtures thereof.
These fats may be chosen in varied ways by those skilled in the art in order to
10 prepare a composition having the sought properties, for example consistency or texture
properties.
The quantity of oil phase may range for example 0.1% to 25%, and for example from 10% to 20% by weight with respect to the total weight of the composition.
15
The composition according to the invention may be in any galenical form normally used in the cosmetics field, and in particular in the form of an aqueous or aqueous-alcoholic solution, optionally gelled, a dispersion of the lotion type, optionally a two-phase dispersion, an oil-in-water or water-in-oil or multiple (W/O/W or OA/V/O for example)
20 emulsion, an aqueous gel, a dispersion of oil in an aqueous phase by means of spherules,
these spherules possibly being polymer nanoparticles such as nanospheres and nanocapsules, or, better still, lipid vesicles of ionic and/or nonionic type; aqueous or oily gel. These compositions are prepared according to the usual methods.
The composition used according to the invention may constitute a skincare
25 composition, and in particular a cleansing, protecting, treating or care cream for the face,
the hands, the feet, the major anatomical folds or the body (for example day creams, night creams, makeup-removing creams, foundation creams or anti-sun creams); a fluid foundation, a makeup-removing milk, a protective or care body milk or an anti-sun milk; a skincare lotion, gel or mousse, such as a cleansing lotion.
30
The invention also relates to the cosmetic use of a composition of the invention, for depigmenting, lightening and/or bleaching keratin materials, in particular the skin.
The invention further relates to a cosmetic non-therapeutic process for
35 depigmenting, lightening and/or bleaching keratin materials, in particular the skin,

11
comprising a step of applying a composition of the invention onto the keratin materials, in particular the skin.
We will now give concrete examples illustrating the invention, but that are in no
5 way restrictive.
All percentages given in the examples are given by mass, unless specified otherwise, and the temperature is ambient (20°C) and expressed in degrees Celsius unless specified otherwise, and the pressure is atmospheric pressure, unless specified otherwise. 10
The following examples are illustrated by the enclosed figures which are as follows:
Efficacy of mulberroside A, extract A or extract B, corresponds to the line with
triangles;
15 Viability of cells corresponds to the line with filled circles; and
EC50 and EC80 are dotted lines.
In easting (x-axis) are the concentrations of mulberroside A, extract A or extract B, which are tested; in northing (y-axis) are the percentages (viability and efficacy).
20 Figure 1 corresponds to the results obtained with mulberroside A.
Figure 2 corresponds to the results obtained with Morus _alba_ extract B_pf_the
invention.
Figure 3 corresponds to the results obtained with Morus alba extract A. of the Invention. 25
Two Morus alba extracts, i.e. extract A and extract B, were obtained by the following
30 process:
1) White mulberries {Morus alba) were cultivated in China (Chongqing region). 1 kg
of mulberry twigs and branches of the Chinese biomass are mixed with 70%
aqueous ethanoi, in a respective weight ratio of 1:5, and extracted at 70°C,
during 3h, to obtain a liquid extract. The extract is filtered, and the spent biomass
35 is re-extracted for two successive times according to the same process, in order
to obtain a combined liquid extract;

12
2) The combined liquid extract obtained from step 1 is heated at 50°C-60°C to strip
the ethanol and the inventors obtain an aqueous solution that comprises 18 to 20
% (in weight/volume) of the total solids extract.
3) The aqueous liquid extract obtained from step 2 is diluted to 20 L with
5 demineralized water, and then filtered using diatornaceous earth (200g) to afford
a clear liquid extract;
4) the clear Siquid extract from step 3 is dissolved in 1-20% aqueous ethanol and
adsorbed over macroporous resin Diaion HP-20 or Amberlite XAD 1600 N, by
allowing the resin and mixture (sample) to remain undisturbed for 1-4h, and
10 further packed in a glass column with a sintered glass disc and eluted with 5 bed
volumes of demineralized water to remove proteins 1-15%. The column is further eluted using a gradient mixture containing aqueous alcohol and the eluate from 50% aqueous alcohol is collected;
5) Said eluate obtained from step 4 is concentrated to evacuate water and ethanol,
15 and dried to obtain extract _B, which contains <30% Mulberrosides and
oligosaccharides <40%. The inventors obtain a yellow to brown powder that represents extract B.
6) First fraction from step 4 (before water wash, 1-20% aqueous ethanol) is again
20 adsorbed over fresh macroporous resin Diaion HP-20, by allowing the resin and
mixture (sample) to remain undisturbed for 1-4h, and further packed in a glass
column with a sintered glass disc and eluted with 5 bed volumes of
demineralized water to remove proteins 1-15%. The column is further eluted
using a gradient mixture containing aqueous alcohol and the eluate from 50%
25 aqueous alcohol is collected;
7) Said eluate obtained from step 6 is concentrated and dried to obtain extract A,
which contains <40% Mulberrosides and oligosaccharides <50%. Said extract A
is an aqueous liquid extract, which is totally stripped of ethanol and which has a
better concentration of mulberroside A.
30
The yield of such a process is 1-2%.
C_he_mical_com position of Mom salba .Extract
The chemical composition of each extract was determined, and the results are as follows:
35

Parameter Extract B Extract A

13

Mulberroside A 19.60% 36.63%
Mulberroside E 6.18% 6.61%
Cis mulberroside A 0.93% 1.13%
Mulberroside F 0.90% less than 1%
Cis-Oxyresveratrol-3'-0-p-Glucopyranoside 0.93% less than 1 %
trans-Oxyresveratroi-3-Op-Glucopyranoside 1.03% less than 1 %
Oxyresveratrol 0.62% less than 1%
Total Protein 3.49% less than 1 %
Total Sugar 30.28% 47.01%
Water content 5.33% 6.71%
Total fats 2.77% less than 1 %
Tata! Composition 72.06% 83.63%
Specification
Thus, the specification for each extract is ;

Parameter Extracts Extract A
Mulberroside A 15-25% 25-40%
Mulberroside E 4-8% 4-8%
Cis mulberroside A 0.5-2% 0.5-2%
Mulberroside F 0.5-2% less than 1 %
Cis-Oxyresveratrol-3f-0-p-
Glucopyranoside 0.5-2% less than 1%
trans-Oxyresveratrol-3-O-p-Glucopyranoside 0.5-2% less than 1%
Oxyresveratrol 0.3-1% less than 1%
Total Protein 2-5% less than 1%
Total Sugar 20-35% 40-55%
Water content Not More Than 8% Not More Than 8%
Total fats Not More Than 4% less than 1%

14 Example 2: Evaluation of Melanin Inhibition of two Morus alba extracts of the invention, in Indian Melanocyte Model (\M\MMethod
5 Normal Human Epidermal Melanocytes from Indian origin (Lonza, NHEM-lndian) of
passage 3-6, were maintained as per the supplier's protocol. 40000 melanocytes/well of
24 wells were plated on day 1. Cells were treated with 8-10 concentrations of Morus alba
extract A or B (as disclosed in example 1) in fresh media on day 2. Each plate contains
vehicle control (water, DMSO or ethanol) and positive reference Lucinoi at 50uM. After 3
10 days of incubation, a first viability assay (CACEIN-AM) followed by melanin content assay
(Absorbance at 405nm) was performed.
Morus alba extract A or B was tested in duplicate wells of 24 well plates and 3-4 such
15 experiments were repeated. Maximum depigmentation of Lucinoi was set to 100% to
calculate % Whitening and % inhibition of extract. Using XLfit software, EC50 (efficacious
concentration at 50% inhibition) was calculated based on Lucinoi normalization. EC80
(viability at 80%) was calculated based on vehicle control.
20
The results are presented in the table below:

Sample Concentration
Mulberroside A 0,0001% to 0,01%
Morus alba extract B 0,0001% to 0,01%
Morus alba extract A 0,0001% to 0,01%
Mulberroside A solubilized in DMSO was tested at concentration 0,001%. The results are in Figure 1.
At 0,001%, it shows a viability of the cells which is 100% and an efficacy in terms of inhibition of the synthesis of melanin which is 10% inhibition. 30

Mows alba extract B of the invention, sofubilized in DMSO, was tested at concentration 0,001%. The results are in Figure 2.
At 0,001%, it shows a viability of the cells which is 100% and an efficacy in terms of inhibition of the synthesis of melanin which is 90% inhibition.
Moms alba extract A of the invention, solubilized in DMSO, was tested at concentration
0,001%. The results are in Figure 3.
At 0,001%, it shows a viability of the cells which is 100% and an efficacy in terms of
inhibition of the synthesis of melanin which is 80% inhibition.

It results from the above that contrary to mulberroside A, both extracts A and B of the invention are the only ones to present an active depingmentinh activity 80% and 90% inhibition of melanin synthesis at 0,001%, respectively.

CLAIMS

Composition comprising, in a physiologically acceptable medium, at least mulberroside A and mulberroside E.
. Composition according to claim 1, wherein it comprises an extract comprising at least mulberroside A and mulberroside E.
. Composition according to claim 2, wherein the extract comprises at least 15% by
weight of the total weight of the extract, of mulberroside A, preferably at least 17% by weight, preferably from 15% to 40% by weight of mulberroside A.
. Composition according to claim 2 or 3, wherein the extract comprises at least 3% by weight of the total weight of the extract, of mulberroside E, preferably at least 4% by weight, preferably from 4% to 8% by weight of mulberroside E.
. Composition according to any one of claims 1 to 4, wherein it further comprises cis-mulberroside A.
. Composition according to any one of claims 2 to 5, wherein the extract comprises at least 0,2% by weight of the total weight of the extract, of cis-mulberroside A, preferably at least 0,4% by weight, preferably from 0,5% to 2%
by weight of cis-mulberroside A.
. Composition according to any one of the preceding claims, wherein it further comprises at least one compound chosen from mulberroside F, cis-
oxyresveratrol-S'-O-p-glucopyranoside, trans-oxyresveratrol-3-O-p-
glucopyranoside, oxyresveratrol, and their mixtures.
. Composition according to any one of claims 2 to 7, wherein the extract
comprises at least one compound chosen from muiberraside F, cis-
oxyresveratrol-3'-0-p-giucopyranoside, trans-oxyresveratrol-3-O-p-
glucopyranoside, oxyresveratrol, and their mixtures.
'. Composition according to claim 8, wherein the extract comprises, by weight of
the total weight of the extract: at least 0,4%, preferably 0,5% to 2% by weight of mulberroside F, and/or

at least 0,4%, preferably 0,5% to 2% by weight of cis-oxyresveratrol-3'-0-|3-
glucopyranoside, and/or
at least 0,4%, preferably 0,5% to 2% by weight of trans-oxyresveratro!-3-0-(3-
glucopyranoside, and/or
at least 0,2%, preferably 0,3% to 1% by weight of oxyresveratrol.
Composition according to any one of the preceding claims, wherein it comprises a Morus alba extract.
Composition according to anyone of the preceding claims, wherein it comprises a Morus alba twig extract.
Composition according to any one of the preceding claims, wherein the physiologically acceptable medium comprises an aqueous phase and/or an oily phase.
Cosmetic use of the composition according to any one of the preceding claims, for depigmenting, lightening and/or bleaching keratin materials, in particular the skin.
Cosmetic non-therapeutic process for depigmenting, lightening and/or bleaching keratin materials, in particular the skin, comprising a step of applying a composition according to any one of claims 1 to 12 onto the keratin materials, in particular the skin.